Table 1.
Baseline characteristics and UBE2I expression.
| Patient characteristics | The percentage change of UBE2I | P Value | ||||
|---|---|---|---|---|---|---|
| >100 n=27 |
50~100 n=8 |
0 ~ 50 n=24 |
0~ -50 n=23 |
-50 ~ -100 n=23 |
||
| Age, years | 0.102 | |||||
| Median | 60.19 | 66.25 | 62.92 | 62.61 | 64.52 | |
| Range | 51~77 | 48~72 | 44~79 | 50~80 | 43~83 | |
| Sex, No. (%) | 0.552 | |||||
| Male | 23 (85.19) | 6 (75.00) | 17 (70.83) | 15 (65.22) | 18 (78.26) | |
| Female | 4 (14.81) | 2 (25.00) | 7 (29.17) | 8 (34.78) | 5 (21.74) | |
| Histology, No. (%) | 0.776 | |||||
| Adenocarcinoma | 8 (29.63) | 3 (37.50) | 10 (41.67) | 11 (47.82) | 10 (43.48) | |
| Squamous cell carcinoma | 13 (48.16) | 3 (37.50) | 11 (45.83) | 6 (26.09) | 10 (43.48) | |
| Small cell carcinoma | 6 (22.21) | 2 (25.00) | 3 (12.50) | 6 (26.09) | 3 (13.04) | |
| Disease stage, No. (%) | 0.784 | |||||
| c-stage III | 11 (40.74) | 2 (25.00) | 7 (29.17) | 10 (43.48) | 8 (34.78) | |
| c-stage IV | 16 (59.26) | 6 (75.00) | 17 (70.83) | 13 (56.52) | 15 (65.22) | |
| Treatment, No. (%) | 0.346 | |||||
| Anti–PD-1 | 9 (33.33) | 1 (12.50) | 7 (29.17) | 3 (13.04) | 8 (34.78) | |
| Chemotherapy+ anti-PD-1 | 18 (66.67) | 7 (87.50) | 17 (70.83) | 20 (86.96) | 15 (65.22) | |